Second-generation antipsychotics: reviewing the cost-effectiveness component of the CATIE trial.

Journal Article (Journal Article)

The cost-effectiveness component of the 18-month CATIE trial of schizophrenia pharmacotherapy (n = 1460) showed that the first-generation antipsychotic perphenazine was US$300-600 per month less expensive than each of four second-generation antipsychotics, and no less effective across multiple measures. We consider whether or not each of eight potential methodological limitations could weaken this conclusion: follow-up rates, study duration, sample characteristics, the choice of outcome measures, exclusion of patients with tardive dyskinesia from assignment to perphenazine, choice of study drugs and doses, reliance on intention-to-treat analysis, and differences in prestudy treatment. We conclude that results of CATIE are robust to these limitations. Perphenazine seems to have been a more representative choice for first-generation antipsychotic comparison treatment than haloperidol.

Full Text

Duke Authors

Cited Authors

  • Rosenheck, R; Swartz, M; McEvoy, J; Stroup, TS; Davis, S; Keefe, RS; Hsiao, J; Lieberman, J

Published Date

  • April 2007

Published In

Volume / Issue

  • 7 / 2

Start / End Page

  • 103 - 111

PubMed ID

  • 20528436

Electronic International Standard Serial Number (EISSN)

  • 1744-8379

Digital Object Identifier (DOI)

  • 10.1586/14737167.7.2.103


  • eng

Conference Location

  • England